A trial looking at erlotinib after treatment for non small cell lung cancer (RADIANT)
Cancer type:
Status:
Phase:
This trial compared erlotinib to a dummy drug (
) after surgery for non small cell lung cancer (NSCLC).
The trial was open for people to join between 2007 and 2010. The team published the results in 2015. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Doctors treat non small cell lung cancer (NSCLC) that has not spread with surgery if possible. Researchers wanted to find out if having erlotinib (Tarceva) after surgery could help stop the cancer coming back.
Erlotinib is a type of cancer growth blocker called a tyrosine kinase inhibitor (TKI). It blocks receptors called epidermal growth factor receptors (EGFR) on cancer cells. This helps stop the cells getting the signals they need to divide and grow.
This trial was for people whose lung cancer cells had EGFRs. The research team tested for EGFRs before people could take part.
The people taking part were put into a treatment group at random:
- 2 out of every 3 people had erlotinib
- 1 out of every 3 people had a dummy drug (placebo)
The main aims of this trial were to find out:
- if erlotinib after surgery can help stop non small cell lung cancer coming back
- more about the side effects of erlotinib
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
K Kelly and others
Journal of Clinical Oncology, 2015. Volume 33, number 34, pages 4007 – 4014.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Clive Mulatero
Supported by
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
OSI Pharmaceuticals
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
